The dawn of a new era of HAE management

Symposium 19th June 2017 – as part of the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Helsinki, Finland.

This symposium provided an overview of past, current, and future therapies and routes of administration for patients with HAE. Prof Cicardi opened the symposium by welcoming attendees and introducing the main topics of the session. Prof Magerl then focussed on treatments that are currently used for acute and prophylactic management of patients with HAE and highlighted that there is an unmet medical need in terms of better prophylactic treatment options. Prof Craig summarised the clinical evidence gathered over the last decades and shared the key findings and insights that led to our current understanding of the disease and laid the foundations for current and future treatment approaches. Prof Zuraw presented the findings from the pivotal Phase III COMPACT trial that explored the efficacy and safety of a self-administered subcutaneous (SC) nanofiltered C1-esterase inhibitor concentrate (C1-INH[SC]) for the prevention of HAE attacks.

CSL Behring EMJ EAACI Review Article FINAL (Published 30.11.17)

2017-12-07T18:35:23+02:00December 7, 2017|HAEi News|